Fintech PR
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
FinancialNewsMedia.com News Commentary
PALM BEACH, Fla., November 14, 2023 /PRNewswire/ — Oncology drugs include wide range of medications such as targeted therapies, chemotherapy agents, immunotherapies, and hormone therapies to treat cancer. The market growth is attributed to various factors such as the rising prevalence of different type of cancer, increasing new drug launches and product approvals, and growing research activities by pharma companies in this field. According to data published by the American Cancer Society in January 2023, there will be around 1,958,310 cancer patients in the U.S. alone by the end of 2023, a 28.0% increase from 2010. The oncology cancer drugs are primarily used to lower the total number of cancer cells in the body, shrink the tumor size, and reduce the symptoms. According to a report from Fortune business Insights projected that the global oncology drugs market size was valued at USD 184.95 billion in 2022 and is projected to grow from USD 205.52 billion in 2023 to USD 484.32 billion by 2030, exhibiting a CAGR of 13.0% during the forecast period. The report said that the: “The Growing focus on R&D to increase adoption of advanced drug therapies to drive the market growth. The treatment of cancer patients involves efforts to cure the disease, prolong survival, and improve their quality of life. Immune cells play an essential role in tumor progression. Therefore, stimulating immune reactions to tumors is an attractive therapeutic and preventive strategy. Top market players are, hence, investing in the research and development of. immunotherapy to treat various cancers.” Active Biotech Companies active today in markets include: Defence Therapeutics Inc. (OTCPK: DTCFF) (CSE: DTC), Bristol Myers Squibb (NYSE: BMY), Novartis AG (NYSE: NVS), Merck (NYSE: MRK), Roche (OTCQX: RHHBY).
Fortune business Insights added that the: “Increasing prevalence of cancer (will) augment the oncology drugs market growth. The rate of cancer incidence is increasing globally. Various factors responsible for this growth are urbanization, changing diet patterns, tobacco smoking, and extended post-reproductive lifespan. According to the GLOBOCAN 2022, cancer is a growing burden. Around 19.3 million new cancer cases occurred in 2022 worldwide. Furthermore, the cancer burden is projected to rise by 47% (around 28.4 million cases) in 2040. Therefore, the growing occurrence of cancer is expected to foster the global oncology cancer drugs market growth over the forecast period. Furthermore, growing awareness of cancer among the population is expected to favor the global market growth in the coming years.”
Defence Therapeutics Inc. (OTCPK: DTCFF) (CSE: DTC): Defence’S SUCCESSFUL SUBMISSION OF AN Investigational New Drug (IND) Application for AccuTOX® as an injectable ANTICANCER TREATMENT for solid tumors – Defence Therapeutics Inc. (“Defence” or the “Company”), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that it has successfully submitted on November 9, 2023 an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its ACCUM-002TM Dimer CDCA-SV40 commonly named “AccuTOX®“, an injectable anticancer molecule, for the treatment of solid cancer tumors.
AccuTOX® is a derivative of the initial Accum® molecule, which has been reported to target cancer on multiple fronts. AccuTOX® disrupts endosomal membranes resulting in impaired intracellular transport mechanisms. AccuTOX® also triggers genotoxic effects, blocks DNA repair mechanisms normally used by cancer cells to repair its damaged genome and induces a form of immunogenic cell death capable of turning ‘ON’ the immune system. When previously tested in preclinical animal models under the supervision of Dr. Moutih Rafei, AccuTOX® impaired tumor growth resulting in ’70-100% survival’ of animals with solid T-cell lymphoma, melanoma or breast cancer.
The IND application includes data, reports and overview summaries of numerous studies to evaluate the pharmacology, pharmacokinetics, and toxicology of AccuTOX® both in vitro and in vivo, including cancer models. In addition, the application describes the manufacture of the drug substance and drug product to be used in human clinical trials. The main purpose of the IND is to share with the FDA the extensive non-clinical data supporting an acceptable safety profile when AccuTOX® will be first administered to humans. The FDA will review the application and determine the acceptability of the data before Defence begins the Phase I clinical trial, which could be as early as Q1-Q2 2024.
“We are thrilled and excited that Defence has achieved a successful submission on its first IND, which represents an important milestone towards advancing AccuTOX® into the clinic. We look forward to work with clinical investigators at City of Hope to study this important and novel candidate for the treatment of melanoma and potentially other solid tumors,” said Sébastien Plouffe, President & CEO of Defence Therapeutics. “With the continued difficulties encountered in the oncology clinic, we believe that the therapeutic use of AccuTOX® provides a novel and powerful approach to combat cancer,” he added.
The primary objective of this upcoming Phase I clinical trial, when approved, is to identify the best therapeutic dosing range that would allow clinicians to co-administer the AccuTOX® compound with Opdulag®, a BMS product containing both anti-LAG3 and anti-PD-1. Several other secondary parameters including therapeutic efficacy will be monitored in treated patients in preparation for a Phase IIa trial on a basket of tumors. CONTINUED… Read this full Press Releases for Defence Therapeutics at: https://defencetherapeutics.com/news-releases/
In other active biotech developments in the markets this week:
Bristol Myers Squibb (NYSE: BMY) recently announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Breyanzi (lisocabtagene maraleucel) to expand its current indication to include the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received a prior Bruton tyrosine kinase inhibitor (BTKi) and B-cell lymphoma 2 inhibitor (BCL2i). The FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 14, 2024. Priority Review designation underscores the high unmet need and the significant advancement Breyanzi may offer this patient population for which there is no standard of care and limited treatment options.
“Currently, there is no standard of care for people living with relapsed or refractory CLL or SLL after treatment with BTKi- and BCL2i-based regimens, leaving a critical unmet need for a treatment option that provides deep and lasting responses,” said Anne Kerber, senior vice president and head, Late Clinical Development, Hematology, Oncology, Cell Therapy (HOCT), Bristol Myers Squibb. “This FDA acceptance brings us one step closer to offering these patients, for the first time, a personalized, T-cell based treatment option. We’re proud to further our commitment to bring the potential of CAR T cell therapy to more patients, building on Breyanzi’s foundation as a differentiated treatment option that has shown clinical benefit in the broadest array of B-cell malignancies.”
Novartis AG (NYSE: NVS) a global leader in immuno-dermatology and rheumatology, recently announced that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.
HS is a chronic, systemic and often painful skin disease that causes recurring boil-like lumps that may burst into open wounds and cause irreversible scarring, often in the most intimate parts of the body. It may take people living with HS an average of up to 10 years to get a correct diagnosis, which can result in disease progression and significantly impact their quality of life. Until now, there has been only one biologic approved to treat HS.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, recently announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma.
“Patients diagnosed with locally advanced unresectable or metastatic biliary tract cancer face a challenging disease with poor survival outcomes, underscoring the need for new treatment options that may help extend their lives,” said Dr. Marjorie Green, senior vice president and head of late-stage oncology, global clinical development, Merck Research Laboratories. “The CHMP’s positive opinion brings us one step closer to providing a new immunotherapy regimen, which has shown an overall survival benefit compared to chemotherapy alone, to these patients in the European Union.”
Roche (OTCQX: RHHBY) recently announced that its Elecsys® Neurofilament Light Chain (NfL) test for Multiple Sclerosis (MS) received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The Elecsys NfL test is intended to be used as an aid in detection of disease activity in adults (18-55 years old) with Relapsing-Remitting Multiple Sclerosis (RRMS) or Secondary Progressive Multiple Sclerosis (SPMS), providing critical insights for disease management.
“Around 2.8 million people are estimated to live with Multiple Sclerosis1. After diagnosis, many face challenges with managing their disease due to significant gaps in access to testing. This can lead to missed opportunities to detect disease progression in support of treatment optimisation,” said Matt Sause, CEO of Roche Diagnostics. “We are excited about the potential Elecsys NfL has to improve outcomes for MS patients by offering a minimally invasive blood draw that can deliver rapid results.”
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated twenty six hundred dollars for news coverage of current press release issued by Defence Therapeutics Inc.by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: [email protected]
+1(561)325-8757
View original content:https://www.prnewswire.co.uk/news-releases/global-oncology-drugs-market-size-projected-to-reach-484-billion-by-2030-301987047.html
Fintech PR
DAY TWO OF HONG KONG INVESTOR SUMMIT TACKLES MEGATRENDS IMPACTING THE PLANET’S EIGHT BILLION CITIZENS
HONG KONG, Dec. 8, 2023 /PRNewswire/ — The Future Investment Initiative PRIORITY Summit Hong Kong today reconvened leaders from finance and government for a second day to address global matters of concern to humanity.
One thousand global investors, policy makers, innovators and business leaders were joined by counterparts from across Asia to discuss ‘megatrends’ including the unstoppable rise of Asia as an economic power, the impact of technology on lifestyles and jobs, and the deployment of capital between diverse markets and economies.
The day began with a presentation by FII Institute CEO Richard Attias and COO Rakan Tarabzoni of the Priority Compass Report, a global survey of 53,000 people across 23 countries. The survey revealed a sharp drop of 20% worldwide in people’s overall satisfaction with their lives, with respondents reporting concerns over cost of living, loneliness, technology, and climate concerns. 65% of people in countries polled are worried about day-to-day living costs. Loneliness has leaped up the list of concerns, with 41% of Asia’s population reporting frequent feelings of loneliness. 55% of people worldwide are worried about access to affordable and accessible healthcare and climate concerns continue to deepen as 78% of people across the Global South are worried about pollution.
Laurence Moroney, Lead AI Advocate at Google addressed concerns about AI and the risk of biases emerging because of reliance on narrow English language datasets. Moroney pointed out that 60% of information on Web 2.0 is generated by bots.
He also argued that innovators in AI need to account for distinctive local cultural identities in the development of AI models and explained that Google’s Gemini is working to condense and preserve cultures into small models, allowing people to interact with, learn about, and preserve individual distinctive cultures.
A panel discussion on cost of living heard Jerry Li, Founder and Managing Partner eWTP Arabia Capital describe data as the new oil, a resource driving innovation and progress. The 120 zettabytes (120, 000,000,000,000,000,000,000 bytes) generated in 2023 is expected to increase by over 150% in 2025, to 181 zettabytes.
During a panel discussion on the future of work Edith Yeung of Race Capital suggested that AI will free people from doing the things that they do not want to do, freeing them for more meaningful activities. The average person will spend 90,000 hours at work over a lifetime.
Raymond Yuan, CEO & Chairman CTH Group pointed out synergies between blockchain and AI starting to emerge in healthcare, life sciences, as well as financial services. The global Blockchain Market size was estimated to be approximately $7.4 billion in 2022 and the global artificial intelligence market $428 billion.
A panel of leading Asian venture capitalists debated ways in which Asia can grow vibrant and successful startup ecosystems, with $22.3 billion invested in Asian startups between July and September 2023.
Discussing the impact of investment on longevity and ageing Joshua Fink, Founder Luma Group, explained that revolutionary regenerative medicine, inspired by Nobel Prize-winning research, can reverse cells to a pre-disease state, offering hope against genetic diseases.
His Royal Highness Prince Faisal bin Bandar bin Sultan, Chairman, Saudi Esports Federation described the spectacular growth of gaming over the last 20 years at 12% per year. By the end of 2023 it is projected there will be 3.75 billion gamers in the world.
In a ‘titan of industry’ fireside chat with Sir Martin Sorrell, Richard Attias and Sorrell surveyed the global media sector, worth $950 billion, with digital projected to comprise 70% by 2025. On the future of platforms such as TikTok Sorrell explained that with young people’s views being shaped by new forms of social media, issues surrounding data safety and privacy will continue. Discussing ‘hyper personalization’ he pointed out that Coca Cola is thinking about the potential for AI to target individual messages to consumers.
Rakan Tarabzoni, COO, FII Institute presented the summit with FII’s inclusive ESG tool, launched to help companies in emerging markets improve sustainability and help investment capital find current and future performance leaders. The tool, which has been made publicly available will address biases inbuilt in other ESG methods and may unlock a $5.4 trillion funding gap of investments into emerging markets.
In the final session HE Kjell Magne Bondevik former Prime Minister of Norway and President, Oslo Centre for Peace and Human Right declared himself convinced that businesses that take more seriously the concerns of common people will be the businesses that will thrive in the future.
The FII Institute has worked with HKEX and consulting firm Deloitte to offset the carbon emissions generated by the summit, by purchasing credits on the HKEX Core Climate exchange, exemplifying a shared conviction that purposeful markets and business can serve humanity as a force for good.
During the summit BOC International signed a strategic cooperation framework agreement with SPIC International Finance (Hong Kong) Company Ltd. on green finance, bond investment and issuance, and global capital management. The signing was witnessed by Mr. Paul Chan, Financial Secretary of Hong Kong SAR.
The summit, held in partnership with Hong Kong Exchanges and Clearing Limited (HKEX), took place at HKEX Connect Hall.
The FII PRIORITY Summit Hong Kong continues conversations held in Riyadh last month. It is part of an ongoing global programme of summits, to be held next year in Miami (February) Brazil (June) and Africa (September))
Richard Attias, CEO of the Future Investment Initiative Institute said:
“I should like to thank Hong Kong Government, the Hong Kong Exchange and the people of this fabulous city for the welcome they have shown us this week. As the world charts its forward course we must be mindful at every turn of the issues that matter. Whether it’s cost of living, developing new modes of payment, new social media platforms, or poverty, it is investment and innovation that can make the difference. The investors and innovators here this week have taken these issues seriously and the conversations and hard work will continue as we strive for a better tomorrow.”
For media inquiries, please contact:
Email: [email protected]
About FII Institute
The Future Investment Initiative (FII) Institute is a global non-profit foundation driven by data with an investment arm and one agenda: Impact on Humanity. Global and inclusive, we foster great minds from around the world and turn ideas into real-world solutions in four critical areas: Artificial Intelligence (AI) & Robotics, Education, Healthcare and Sustainability.
Photo – https://mma.prnewswire.com/media/2296786/Future_Investment_Initiative_Institute_1.jpg
Logo – https://mma.prnewswire.com/media/1811613/4445856/FII_Institute_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/day-two-of-hong-kong-investor-summit-tackles-megatrends-impacting-the-planets-eight-billion-citizens-302010435.html
VICTORIA, Seychelles, Dec. 8, 2023 /PRNewswire/ — OrangeX, a global cryptocurrency exchange, is proud to unveil its $5 million Innovation Fund. Designed to bolster the Bitcoin ecosystem and propel blockchain innovation, the Fund’s core focus is on investing in promising projects within the Bitcoin ecosystem, including Ordinals Protocols and BRC-20 standard tokens.
In the dynamic landscape of the evolving Bitcoin ecosystem, various features and functionalities are continually reshaping its potential. Notably, the BRC-20 token standard has emerged as a key player, attracting significant attention.
Recognizing the surging demand and immense potential of BRC-20 standard token projects, OrangeX’s Innovation Fund stands ready to provide crucial capital and infrastructure support to empower the community in building a resilient and flourishing Bitcoin ecosystem.
Exciting Bitcoin Ecosystem Initiatives
OrangeX is proud to introduce a range of products and services tailored for the Bitcoin ecosystem and projects, catering to user preferences. Key offerings include:
- Bitcoin-based Token Trading: Facilitating the listing and trading of Bitcoin-based tokens. ORDI, the largest BRC-20 token, is now available on both OrangeX Spot and Perpetual Contracts.
- Bitcoin Ecosystem Information: Providing valuable insights and analytics on the Bitcoin ecosystem.
- Bitcoin Ecosystem Token Launchpad: Offering a fair and efficient token distribution service for promising Bitcoin ecosystem projects with financial, technical, and marketing assistance. Share early ecosystem returns with a larger customer base. Interested project owners can contact [email protected] for more information.
OrangeX CEO, Alexandra K, expressed confidence in the potential of outstanding Bitcoin Ecosystem projects. He stated, “These projects not only stand to receive financial backing from OrangeX but also gain access to a suite of services, resources, and connections available through our platform. With these tools, we believe our supported projects will thrive, succeed, and have a positive impact on the world.”
Empowering the Bitcoin Ecosystem: OrangeX’s Pioneering Role
Bitcoin, the original cryptocurrency, remains the bedrock of blockchain finance. Every trading platform benefits from the development of Bitcoin. If there is no Bitcoin, cryptocurrency exchange will no longer exist. With 15 years since its inception, the Bitcoin revolution continues to unfold, presenting a dynamic and evolving ecosystem. Anticipate groundbreaking innovations that will redefine possibilities.
As a central figure in this domain, every cryptocurrency exchange is urged to actively contribute to the ongoing development of the Bitcoin ecosystem. OrangeX, as a trailblazer, introduces the Innovation Fund, a platform committed to integrating Bitcoin ecosystem products. This initiative aims to address user needs in exchanging, managing, and investing in Bitcoin-based projects.
OrangeX invites collaboration from institutions, communities, and projects to join forces in propelling the growth and diversification of the Bitcoin ecosystem. Together, let’s forge a future where Bitcoin is more accessible, versatile, and inclusive – ensuring its enduring significance in the ever-evolving landscape of blockchain-based finance.
About OrangeX
Founded in 2021 in Seychelles, OrangeX stands as a worldwide cryptocurrency trading platform renowned for its cutting-edge technology, proficient team, and seasoned financial knowledge. With more than 1 million active users, OrangeX has built a comprehensive product line, dedicated to empowering investors to make a better future. OrangeX futures trading offers 3 service options: USDT-M Perpetual Contracts, One-Click Copy Trading and Powerful API. According to Coinmarketcap(CMC) and CoinGecko, OrangeX Spot now supports over 100 coins with approximately 130 trading pairs.
For more information, please visit: Website | Twitter | Telegram | CoinMarketCap | CoinGecko
For media inquiries, please contact: [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/orangex-unveils-5m-innovation-fund-accelerating-support-for-bitcoin-ecosystem-growth-302010284.html
SHENZHEN, China, Dec. 8, 2023 /PRNewswire/ — On December 8, the 2023 Shenzhen Global Investment Promotion Conference was held in Shenzhen, China. Over 380 projects were signed, with a total investment of 1 trillion yuan. The event was attended by more than 1,000 distinguished guests from countries and regions including the United States, Japan, and the EU.
Shenzhen, an open city, is extending invitations to global investors. Under the theme of “Create New Paradigms, Embrace Shared Opportunities — Invest in Shenzhen, Build a Winning Future”, the Conference took place in the format of “1+1+12+N” events, according to the Commerce Bureau of Shenzhen Municipality. Specifically, it consists of one main event, namely the Investment Promotion Conference and the Shenzhen City Summary Meeting on Investment Promotion; one Investment Outcome Exhibition Area; 12 district-level investment promotion conferences; and several overseas parallel sessions and industrial investment promotion activities. Ten overseas parallel sessions were staged in Madrid, Zurich, Hawaii, Vancouver, San Diego, Brisbane, Chicago, Tokyo, Sydney, and Milan. 12 industry investment promotion activities were held on various topics, including energy storage, digital energy, finance, consumption, talent attraction, and high-tech industries.
A favorable business environment serves as the best “Chinese parasol tree”, the greatest “magnet”, and the core competitiveness of a city. The Conference showcased investment opportunities and policies for investing in Shenzhen as well as presented Shenzhen’s first-class business environment to the world. Shenzhen has ranked among the top in China’s business environment evaluations for all 18 indicators. With a flourishing private economy, Shenzhen boasts a total of 4.16 million registered business entities and ranks first nationwide for the total quantity and density of entrepreneurship.
The excellent business environment has made Shenzhen a popular land for international investment, and multinational companies maintain promising prospects for investment in the city. Thomas Triomphe, Global Executive President of Sanofi Pasteur, expressed confidence in the tremendous potential Shenzhen holds for the future. “This is an incredible city. The technological and economic development in Shenzhen has been impressive over the past few years,” said David Kohler, Chairman and CEO of Kohler Group.
This year, the Conference set up the Investment Outcome Exhibition Area for the first time to present the investment outcomes and development plans of the districts and departments of the city in recent years. An area was also set up for an exhibition on local renowned brands to display products in advanced manufacturing, consumer electronics, trendy lifestyles, and the new-style tea industry.
View original content:https://www.prnewswire.co.uk/news-releases/the-2023-global-investment-promotion-conference-held-in-shenzhen-china-302010240.html
-
Fintech5 days agoNOVASPARKS EXPANDS ITS OPERATIONS IN ASIA-PACIFIC
-
Fintech PR4 days agoJIVF partners with OpenWay for game-changing fintech transformation
-
Fintech5 days ago
Broadridge Investment Management Technology Enhances Carlyle’s Private Credit and CLO Portfolio Management Operations
-
Fintech PR4 days agoOnly 20% of companies globally are meeting their carbon reduction targets, and many acknowledge need for “complete transformation,” according to ENGIE Impact report
-
Fintech PR4 days agoEY modelling reveals multiple energy transitions accelerating around the world, but handbrakes risk progress
-
Fintech PR4 days agoThe Winter issue of World Finance magazine has been published – offering its usual wealth of in-depth and high-quality journalism on a diverse mix of financial topics from across the globe
-
Fintech PR4 days ago
BingX Appoints Vivien Lin as Chief Product Officer to Elevate User Experience
-
Fintech PR4 days agonShift unveils seven major trends that will impact ecommerce in 2024
